Literature DB >> 3402522

Differential effect of type I and type II diabetes on antipyrine disposition in man.

T Zysset1, H Wietholtz.   

Abstract

As the influence of diabetes on drug metabolism in patients is controversial, a study was performed to assess antipyrine (AP) disposition in controlled Type I and Type II diabetics and 2 age- and sex-matched control groups. In Type I diabetics, the half-life of AP was significantly reduced from 12.0 (controls) to 7.9 h, and the volume of distribution (V) was lowered from 733 to 569 ml.kg-1. The resulting plasma clearance and cumulative urinary excretion of AP and its metabolites over 24 h did not differ from controls. In Type II diabetics, the AP half-life (14.5 h) and V (568 ml.kg-1) did not differ from their age- and sex-matched controls (11.1 h and 643 ml.kg-1, respectively), but the plasma clearance of AP was significantly reduced by 30%, and urinary excretion was significantly reduced to 44% of controls. The differential effects of Types I and II diabetes on AP metabolism may explain, at least in part, the controversial data in the literature.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402522     DOI: 10.1007/bf00542438

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  A study on the physiological disposition of acetophenetidin by the diabetic man.

Authors:  R M Dajani; S Kayyali; S E Saheb; A Birbari
Journal:  Comp Gen Pharmacol       Date:  1974-03

3.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

4.  Influence of diabetes mellitus on drug metabolism in man.

Authors:  H Daintith; I H Stevenson; K O'Malley
Journal:  Int J Clin Pharmacol Biopharm       Date:  1976-01

5.  Effect of diabetes on rat liver cytochrome P-450. Evidence for a unique diabetes-dependent rat liver cytochrome P-450.

Authors:  M R Past; D E Cook
Journal:  Biochem Pharmacol       Date:  1982-10-15       Impact factor: 5.858

6.  Liver function tests in diabetic patients.

Authors:  P I Salmela; E A Sotaniemi; M Niemi; O Mäentausta
Journal:  Diabetes Care       Date:  1984 May-Jun       Impact factor: 19.112

7.  Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.

Authors:  M W Teunissen; P Spoelstra; C W Koch; B Weeda; W van Duyn; A R Janssens; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

8.  The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus.

Authors:  P I Salmela; E A Sotaniemi; R O Pelkonen
Journal:  Diabetes       Date:  1980-10       Impact factor: 9.461

9.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

10.  6 beta-Hydroxycortisol: a noninvasive indicator of enzyme induction.

Authors:  P Saenger; E Forster; J Kream
Journal:  J Clin Endocrinol Metab       Date:  1981-03       Impact factor: 5.958

View more
  14 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism.

Authors:  Jie Gao; Wen Xie
Journal:  Drug Metab Dispos       Date:  2010-08-24       Impact factor: 3.922

3.  Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism.

Authors:  H Wietholtz; T Zysset; K Kreiten; D Kohl; R Büchsel; S Matern
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans.

Authors:  P R Gwilt; R R Nahhas; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

5.  Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus.

Authors:  T Zysset; H Wietholtz
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Antipyrine kinetics in undernourished diabetics.

Authors:  J C Shobha; T C Raghuram; A D Kumar; K Krishnaswamy
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes.

Authors:  Bingning Dong; Mohammed Qatanani; David D Moore
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

8.  Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats.

Authors:  J Emami; F M Pasutto; F Jamali
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

9.  Disposition of lorazepam in diabetes: differences between patients treated with beef/pork and human insulins.

Authors:  R J Herman; A Chaudhary; C B Szakacs; D Woo; R Lane; M A Boctor
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Cyclosporine pharmacokinetics and effect in the type I diabetic rat model.

Authors:  L J Brunner; L V Iyer; K Vadiei; W V Weaver; D R Luke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.